Alize RP is a partner of HTID® – 24 & 25 June 2019

On June 24 and 25, 2019, the first edition of the HealthTech Investor Days (HTID®) will take place, organized by France Biotech.

The event will bring together the most promising HealthTech companies (Biotech, Medtech, E-Health, Artificial Intelligence), major pharmaceutical groups and international investment funds. No less than 450 international actors will gather in Paris to discuss and exchange views on the European HealthTechs sector.


HTID® is a unique platform in Europe for exchanges between innovative HealthTech companies, international financiers and major healthcare companies. The objective of this event is to multiply synergies and collaborations between all these players and to accelerate the launch of new drugs and new therapeutic solutions” explains Maryvonne Hiance, President of France Biotech, the association behind the event.


The HealthTech sector in Europe is important and health innovations are a major economic and industrial driver. There are 3000 biotechs and more than 25 000 medical technology companies, it represents the European vitality in terms of health innovation. The most mature companies have developed innovations with immense medical potential that must be further developed.


The HealthTech sector requires larger and longer funding than other innovation sectors. This is naturally due to the regulatory obligations governing health products. Europe offers an ecosystem that is fertile for innovation, but fundraising for European medtechs and biotechs (6.2 billion €) represents just under a third of the fundraising in the United States (19.8 billion €).


For more information on HTID:

Press Release : Click here

HTID program : Click here

Stilla Technologies, Yuzi Holdings and TusPark donate digital PCR Naica™ Systems to help fight coronavirus outbreak in China
Bayer, Meiogenix collaborate to accelerate agricultural innovation through the development of unique technologies
Other news
Median Technologies records its best quarterly performance and joins forces with biopharmaceutical companies in the fight against Covid-19.
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies
Hungary and the Netherlands approve Lipiodol® Ultra Fluid for hysterosalpingography in women undergoing infertility workup
Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company’s strategy for innovation and partnerships